BioSpace News Archive

Relievant Medsystems Announces First Patient Enrollment in the INTRACEPT Clinical Study

Steven R. Garfin, M.D. is named the principal investigator of the study.

October 25, 2017
·
5 min read
Business

Ossur Hf: Q3 Results 2017

Sales in the third quarter of 2017 amounted to USD 139 million.

October 25, 2017
·
2 min read
Business

Idera Pharmaceuticals Provides Corporate Governance Update

Youssef El Zein, Managing Partner of Pillar Invest Corporation has elected to step down from the company’s Board of Directors, effective immediately.

October 25, 2017
·
4 min read
Genetown

Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock

The company intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In connection with this offering.

October 25, 2017
·
4 min read
Business

Invuity Announces 2017 Third Quarter Financial Results and Conference Call Date

The Company will host a conference call to discuss the financial results and other business developments.

October 25, 2017
·
1 min read
Business

Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017

The audio webcast can be accessed under “Events and Presentations” in the Investor Relations section of the Company’s website.

October 25, 2017
·
4 min read
Business

Genmab Announces Additional Information Concerning Net Sales of DARZALEX (daratumumab) for Third Quarter of 2017

October 25, 2017
·
6 min read
Business

Notal Vision Welcomes Distinguished Retinal Specialist John S. Pollack, MD, to the Board of Directors

Notal Vision today announced that John S. Pollack, MD, an internationally recognized retinal clinician, surgeon, and educator, has been elected to Notal’s Board of Directors.

October 25, 2017
·
4 min read
Drug Development

Neurocrine Initiates Phase IIb Clinical Study of Once-Daily INGREZZA in Children And Adolescents With Tourette Syndrome

Neurocrine announced today that it has initiated a Phase IIb clinical trial, T-Force GOLD, for INGREZZAr, in children and adolescents with Tourette syndrome.

October 25, 2017
·
6 min read
Business

Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th

Vermillion announced today that it will report its third quarter 2017 financial results on Wednesday, November 8, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

October 25, 2017
·
1 min read